BiondVax is a publicly traded, innovative biopharmaceutical company developing a Universal Flu Vaccine, designed to provide multi-season and multi-strain protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
BiondVax’s go-to-market strategy for its lead candidate M-001, universal flu vaccine is to initially obtain regulatory approval as a primer to a pandemic or seasonal vaccine, and following the accumulation of enough data, to test and gain approval as a universal standalone vaccine.
Learn more about the Flu
See our short movie to learn more about the flu virus and how today’s vaccine don’t go far enough in protecting us.
Featured on Israeli TV
On August 13, BiondVax was featured on the main Israeli news show, Mabat. You can view this (subtitled) segment below.